Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000726457 | SCV000344805 | pathogenic | not provided | 2018-01-12 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000726457 | SCV001152339 | likely pathogenic | not provided | 2016-05-01 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003463778 | SCV004196498 | pathogenic | Miyoshi muscular dystrophy 1 | 2023-07-06 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003736690 | SCV004517950 | pathogenic | Qualitative or quantitative defects of dysferlin | 2023-06-28 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Gln1470*) in the DYSF gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in DYSF are known to be pathogenic (PMID: 17698709, 20301480). This variant is present in population databases (no rsID available, gnomAD 0.006%). This premature translational stop signal has been observed in individual(s) with DYSF-related conditions (PMID: 33610434). ClinVar contains an entry for this variant (Variation ID: 290284). For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV005025440 | SCV005659321 | pathogenic | Miyoshi muscular dystrophy 1; Autosomal recessive limb-girdle muscular dystrophy type 2B; Distal myopathy with anterior tibial onset | 2024-04-02 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000306643 | SCV000792411 | likely pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2B | 2017-06-22 | no assertion criteria provided | clinical testing |